[Applauso] [Musica] [Applauso] La malaria è la principale causa di morte al mondo per parasitosi. Ogni anno provoca 600.000% morti. L'80% dei bambini al di sotto dei 5 anni ancora oggi muore di malaria.L'Organizzazione Mondiale della Sanità dice: "È urgente la scoperta di nuovi farmaci antimalarici, i farmaci che attualmente vengono utilizzati per la cura della malaria e il parasita sta diventando resistente a questi farmaci. Uno dei farmaci che viene utilizzato è estratto da una pianta che cresce ai bordi ...

[Applauso] [Musica] [Applauso] [Musica] Ho iniziato a occuparmi di dipendenze circa oltre 35 anni fa. indirettamente me ne sono occupato anche prima perché io provengo da una città che un tempo era definita la Bangkok in Rivaladige, una bellissima città a Verona e appartengo, per una questione anagrafica, a quella generazione che è cresciuta, che ha esordito nell'adolescenza insieme all'esordiente diffusione dell'eroina. Poi professionalmente ho iniziato a occuparmi lavorando nelle comunità di Saman, fondat ...

[Music] [Applause] So artificial intelligence is reshaping our world. Currently it is changing how we predict the weather, how we detect diseases, how we access loans or produce music, but even how we fight in wars. More and more frequently, artificial intelligence is deciding what we buy, what we watch in the evening when we are tired, but even who we interact with on social media.And this is why we must ask ourself whose world is this artificial intelligence reflecting. AI is no longer just a tool. Right ...

[Musica] [Applauso] Vi racconto una storia e come per tutte le storie c'è bisogno di un luogo adeguato, di un bel pubblico, di un giusto tempo che superi l'idea di Chronos. C'è bisogno di un dream nella suggestione della cultura degli aborigeni australiani, quella che chiamano il tempo del sogno. Siccome io oggi vi parlo di sogni, permettetemi di suonare questo strumento australiano e provare a creare insieme un piccolo e speriamo significativo dream [Musica] [Musica] เ Ah.[Musica] Marco, lui aveva 10 anni ...

Deepfakes use the voices and faces of public figures to create videos on social media that look and sound incredibly real but are actually fake. This can leave some viewers vulnerable to scams, misinformation, and more. McAfee's video scam protection, a part of McAfee's scam detector feature that is now included on all McAfee Plus plans, keeps those viewers informed by detecting and alerting users to audio that has been manipulated by AI.By leveraging AMD Ryzen AI Pro's powerful NPU, McAfee's AI models can ...

Global Research Risk and Alpha amid Rising Volatility Cathy Fang Analyst S1460518100001 cathy.fang@ubs.com +86 21 3866 8891 July 2025 This document has been prepared by UBS Securities Co. Limited. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. ...

July 4, 2025 08:34 AM GMT WuXi Biologics Cayman Inc | Asia Pacific M Update Pushing the Envelope in High- Concentration Biologics Manufacturing Key Takeaways The highest-concentration biologic approved to date is Benlysta (belimumab): High-concentration is defined as levels exceeding 100mg/mL. Humira (adalimumab), for example, has a concentration level of 100mg/mL. Benlysta, GSK's novel treatment for lupus, is manufactured at 200mg/mL. WuXi's new platform is able to engineer concentrations of up to 230mg/mL ...

July 3, 2025 10:29 AM GMT Multi-Industry | North America CoTD: No Import Wave 90 Days Later Chart of the Day (CoTD) highlights charts that tie into latest investor conversations, are timely for the macro + company events, or just ones that we find interesting. Exhibit 1: US Imports (YoY, trail 30d) - After ~20% yoy growth from December - March, imports flat-lined in April - May but are tracking sharply lower in June Source: Morgan Stanley Research, AlphaWise, UN Global Platform; PortWatch While the lead up ...

Barostim Device & Clinical Trial Results - Barostim improves exercise capacity in HFrEF patients, showing a 19%-20% improvement versus the control arm in clinical trials[19, 37] - The BeAT-HF pivotal trial demonstrated a clinically meaningful improvement of 60 meters in exercise capacity and a -14 point change in quality of life for Barostim patients[27, 28] - The BeAT-HF pivotal trial showed a 25% reduction in NT-proBNP levels with Barostim, which is considered clinically meaningful[34] Market Opportunity & Patient Identification - The initial annual market opportunity for Barostim in the U S and the five largest EU countries is estimated at $2 9 billion[44] - The U S market consists of 6 3 million patients, while the 5 EU countries have 8 6 million patients[42] - The initial addressable patient incidence rate is 55,000 patients per year in the U S and 61,000 patients per year in the 5 EU countries[42] - Patient identification for Barostim is straightforward, based on NYHA II/III symptoms, LVEF ≤ 35%, and NT-proBNP < 1600pg/ml[47] Commercial Strategy & Financial Performance - The company aims to add 3 new account managers every quarter to create new territories and activate implanting centers[58] - The goal is to have 5 active implanting centers per territory, with each center implanting 12 Barostim units per year[58] - Full year 2022 revenue was $7 0 million - $7 1 million, with US HF revenue at $5 9 million (+118%)[67] - The company projects total revenue between $35 0 million and $38 0 million for the full year of 2023[68]

Market Opportunity & Disease Burden - Heart failure affects over 6 million people in the U S [9], leading to over 1 1 million hospital discharges and over 1 3 million emergency room visits annually [11] - The annual costs associated with heart failure are expected to reach $70 billion by 2030 in the U S [11] - The U S annual net addressable market for Barostim is estimated at $2 2 billion, assuming an average selling price (ASP) of $29,000 [37] Barostim Therapy & Clinical Evidence - Barostim is presented as a neuromodulation therapy designed to improve heart failure symptoms [8] - Barostim implantation is a 60-minute procedure with a 97% freedom from major complications [46, 48] - Real-world evidence demonstrates an 85% relative reduction in hospital visits per year post-Barostim implant (average 1 92 years) compared to pre-implant (12 months) [67] Financial Performance & Guidance - Worldwide revenue for 2024 was $51 3 million, representing 31% growth [87, 88] - The gross margin for 2024 was 84% [87, 88] - The company's revenue guidance for full year 2025 is $55 0 – $58 0 million, with a gross margin of 83% – 84% and operating expenses of $95 0 – $98 0 million [90]